Ipamorelin 10mg Nasal Spray

Ipamorelin nasal spray supplies the pentapeptide Aib-His-D-2-Nal-D-Phe-Lys-NH2, CAS 170851-70-4, molecular weight 711.85, as a metered aqueous solution. Two of its five residues are not proteinogenic. That means the standard amino acid analysis most laboratories run will not see them.

Specification Table

Why Do the Non-Coded Residues Matter for Verification?

Two of the five residues here do not appear in any protein, and that fact quietly breaks one of the standard analytical methods.

Amino acid analysis works by hydrolysing a peptide to free residues and separating them against a calibration standard containing the twenty proteinogenic amino acids.

Aib and D-2-naphthylalanine are not in that standard. They will elute somewhere, but without a reference peak there is nothing to identify or quantify them against.

A laboratory running routine amino acid analysis on this compound sees histidine and lysine, sees two unassigned peaks, and has confirmed almost nothing about the sequence.

The method also cannot distinguish D from L configuration. So the D-phenylalanine at position 4 reads as ordinary phenylalanine and the stereochemistry that matters pharmacologically goes unchecked.

Verification therefore has to rest on mass spectrometry against 711.85 and on chromatographic comparison with a characterised reference, not on residue composition.

Chiral analysis exists and can confirm the D residues, but it is a separate method that most suppliers do not run and most buyers do not ask about.

What Does Aib Contribute Structurally?

The first residue is the smallest structural modification in this catalogue and one of the most consequential.

Aib is alanine with a second methyl group on the alpha carbon, making that carbon quaternary, and it has no side chain to speak of and no stereocentre at all.

That substitution sharply restricts the backbone angles the residue can adopt, biasing the local conformation toward a helical turn and reducing the flexibility of the chain around it.

Rigidity at the amino terminus does two things. It obstructs aminopeptidases, which need a flexible extended substrate, and it holds the rest of the molecule in a more defined shape for receptor binding.

The C-terminal amide closes the other end against carboxypeptidases, leaving a five-residue molecule with both termini defended.

Aib appears elsewhere in modern peptide design for exactly these reasons. It is a recurring feature of compounds intended to survive in circulation.

For a spray, the practical consequence is that enzymatic degradation at the nasal mucosa is less of a limitation here than for a conventional peptide of similar size.

Worth noting that the Aib substitution is also what makes this compound awkward to synthesise. A quaternary alpha carbon is sterically hindered, so coupling the next residue onto it proceeds slowly and often incompletely.

The practical consequence is a deletion impurity missing the Aib entirely, roughly 85 daltons lighter at about 626.8, arising from chains where the final coupling failed.

That species would retain the histidine, both D residues and the lysine, so it looks correct by amino acid analysis and differs only in mass. Asking whether the chromatogram shows anything near 627 is the specific question for this molecule.

The same hindrance argument applies in reverse to stability. A quaternary carbon has no alpha hydrogen, which removes one of the racemisation pathways that troubles ordinary residues during synthesis and storage.

So the residue that makes the compound difficult to build is also part of what makes it durable once built. That trade is common in peptide design and it is rarely spelled out on a product page.

How Does 712 Daltons Affect the Nasal Route?

This is among the smaller compounds in the spray range, which places it favourably on the one variable that most reliably predicts transnasal transport.

Nasal absorption declines steeply with molecular weight, with the practical transition around 1,000 daltons where paracellular passage between epithelial cells becomes inefficient.

At 711.85 daltons this compound sits comfortably below that transition, smaller than Melanotan II at 1,024 and Kisspeptin-10 at 1,302.

The two bulky aromatic residues raise its hydrophobicity, which generally favours transcellular passage across the lipid membrane as an additional route.

Against that, the lysine and histidine give a net positive charge at physiological pH, and a negatively charged mucosal surface binds cationic molecules rather than passing them.

Published intranasal pharmacokinetic data for this compound specifically is not established, and the favourable size argument is a prediction rather than a measurement.

What ipamorelin nasal spray does provide is a metered volume, which removes the reconstitution arithmetic that a lyophilized vial requires. What reaches the mucosa still depends on plume geometry and drainage.

What Ipamorelin Nasal Spray Dosage Figures Are Published?

Every figure below is an amount used in a published study, in the species that study used.

The original characterisation work from the Novo Nordisk group used parenteral administration in rodents and swine, with amounts in the microgram per kilogram range.

Later work has generally stayed in that band by subcutaneous or intravenous routes. Intranasal figures for this compound are not established in the peer-reviewed record.

Extrapolating a subcutaneous figure to an intranasal one requires an absorption fraction that has not been measured for this molecule. So the conversion cannot be done honestly.

Interspecies conversion needs allometric scaling by body surface area rather than body-weight arithmetic, and the difference between the two methods is substantial.

The spray format adds variables the vial does not carry, since metered volume, concentration, plume geometry and drainage all sit between an actuation and a deposited amount.

No figure here should be read as a recommendation. These are reference points from published studies conducted under specific conditions.

What Distinguishes Ipamorelin From the GHRP Compounds?

The comparison with GHRP-2 and GHRP-6 is the most cited point about this molecule and it rests on a specific published claim.

All three act at the growth hormone secretagogue receptor GHS-R1a, so they occupy the same receptor class and are often grouped together.

The characterisation work reported that this compound produced growth hormone release without a measurable rise in ACTH, cortisol or prolactin, whereas the GHRP compounds produced those additional effects.

That selectivity claim is the reason the compound was developed and the reason it remains of research interest, and it is a falsifiable statement rather than a general assertion.

The structural basis is not fully resolved. The two D residues and the Aib produce a different presentation at the receptor, but no published structure explains the selectivity mechanistically.

Anyone testing that claim needs the appropriate hormone panels rather than growth hormone alone, which is the whole point of the comparison.

It also means a preparation with incorrect stereochemistry at positions 3 or 4 might retain some receptor activity while losing the selectivity, and nothing on a standard certificate would reveal that.

How Does the Spray Compare With a Reconstituted Vial?

The format decision here turns on measurement rather than on chemistry, since the molecule is stable enough that either format survives ordinary handling.

A lyophilized vial requires the researcher to choose a diluent, add a measured volume and calculate a resulting concentration, and each of those steps carries its own error.

The advantage is that the concentration is then known and controlled, and the material spends only the working period in solution.

A spray arrives at a concentration set by the manufacturer, in a solution that has been aqueous since the fill line, delivering a fixed metered volume per actuation.

The metered volume is the real convenience. It removes pipetting variability from the delivery step and makes repeated applications more consistent than manual measurement would.

What it does not remove is the gap between what leaves the nozzle and what reaches the mucosa, which depends on plume geometry, application angle and drainage to the throat.

For a compound with no established intranasal pharmacokinetics, that gap is the dominant uncertainty and it is present in both formats equally.

The sensible position is that the spray simplifies delivery and the vial simplifies concentration control, and which matters more depends entirely on the experiment.

How Should the Spray Be Stored and Recorded?

Ipamorelin nasal spray is chemically undemanding, which makes the storage requirements short and the record-keeping the more important half.

Refrigerate at 2 to 8 degrees Celsius, protect from light and do not freeze a solution-state product.

There is no cysteine, no methionine and no asparagine-glycine motif, so the thiol oxidation, thioether oxidation and deamidation routes that trouble other compounds here do not apply.

The naphthalene side chain is the main photolabile feature, which is the reason light protection is worth taking seriously rather than treating as boilerplate.

Both termini are blocked, so exopeptidase activity introduced by contamination has no purchase, and the principal risk in an opened bottle is microbial growth.

Record the lot, the stated concentration, the date first opened, the storage temperature and the actuation count for each experiment.

For this compound the certificate question worth asking is whether chiral purity was assessed at all, since that is the field most likely to be absent and the one the pharmacology depends on.

Published Literature

Selected references verified against the publisher record.

1. (‘Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561.’, ‘https://doi.org/10.1530/eje.0.1390552’)
2. (‘Andersen NB, Malmlof K, Johansen PB, et al. The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation. Growth Horm IGF Res. 2001;11(5):266-272.’, ‘https://doi.org/10.1054/ghir.2001.0239’)
3. (‘Howard AD, Feighner SD, Cully DF, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996;273(5277):974-977.’, ‘https://doi.org/10.1126/science.273.5277.974’)
4. (‘Illum L. Nasal drug delivery: new developments and strategies. Drug Discov Today. 2002;7(23):1184-1189.’, ‘https://doi.org/10.1016/S1359-6446(02)02529-1’)

Frequently Asked Questions